BCM
LXRX icon

BlueCrest Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

BlueCrest Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-12,794
Closed -$71K – 787
2019
Q1 		$71K Buy
+12,794
New +$77.7K ﹤0.01% 1109

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

BlueCrest Capital Management's LXRX Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2019, closing a stake of 12,794 shares — an estimated $71K sold.

BlueCrest Capital Management first reported a position in LXRX in Q1 2019 and held it in 1 quarter. The position peaked at $71K in Q1 2019. 109 funds tracked by Wall St. Rank hold LXRX as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 12,794 Lexicon Pharmaceuticals shares in Q2 2019, an estimated $71K.
  • BlueCrest Capital Management first reported a position in Lexicon Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Lexicon Pharmaceuticals position peaked at $71K in Q1 2019.
  • 109 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.